Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04088760 · ClinicalTrials.gov registry record · Phase 2
TCRαβ+/CD19+ Depleted Allogeneic Hematopoietic Stem Cell Transplantation for Malignant and Non-malignant Disorders
A Phase 2 study, sponsored by Children's Hospital Medical Center, Cincinnati.
- Terminated
- Registry status
- Phase 2
- Development phase
- 15
- Enrollment target
NCT04088760 is a Phase 2 study that was terminated before completion, run by Children's Hospital Medical Center, Cincinnati. The registered enrollment target is 15 participants.
The verdict
NCT04088760, a Phase 2 study, was terminated before completion, sponsored by Children's Hospital Medical Center, Cincinnati.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 15 participants
- Enrollment target
Study Summary
The purpose of this study is to investigate the safety and efficacy of TCRαβ+/CD19+ depleted allogeneic hematopoietic stem cell transplant (HSCT) for malignant and non-malignant disorders in children and adolescent/young adult patients using the CliniMACS® immunomagnetic selection device (Miltenyi Biotec).
Interventions
- DRUG TCRαβ+/CD19+ depleted allogeneic hematopoietic stem cell transplant (HSCT)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2019-09-16 |
| Est. Completion | 2021-09-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04088760
The ClinicalTrials.gov registry entry for NCT04088760 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Children's Hospital Medical Center, Cincinnati, which has 571 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which TCRαβ+/CD19+ depleted allogeneic hematopoietic stem cell transplant (HSCT) is the first listed.
NCT04088760 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04088760 about?
NCT04088760 is a clinical study titled "TCRαβ+/CD19+ Depleted Allogeneic Hematopoietic Stem Cell Transplantation for Malignant and Non-malignant Disorders". The purpose of this study is to investigate the safety and efficacy of TCRαβ+/CD19+ depleted allogeneic hematopoietic stem cell transplant (HSCT) for malignant and non-malignant disorders in children and adolescent/young adult patients using the CliniMACS® immunomagnetic selection device (Miltenyi B...
What is the current status of trial NCT04088760?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2019-09-16. Estimated completion is 2021-09-03.
What interventions are being tested in trial NCT04088760?
The interventions under investigation include: TCRαβ+/CD19+ depleted allogeneic hematopoietic stem cell transplant (HSCT) (DRUG).
Who is sponsoring clinical trial NCT04088760?
This trial is sponsored by Children's Hospital Medical Center, Cincinnati, which has 571 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.